Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dronedarone
- Development stage
- Approved
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Dronedarone is a class III antiarrhythmic small molecule developed by Sanofi-Aventis for the management of atrial fibrillation (AF) and atrial flutter (AFL). Chemically, it is a deiodinated benzofuran derivative of amiodarone, designed to reduce the adverse effects associated with amiodarone’s iodine content. Dronedarone acts as a multichannel blocker, inhibiting multiple cardiac ion channels including potassium (rapid delayed rectifier, slow delayed rectifier, ACh-activated inward rectifier), sodium (fast inward), and L-type calcium channels. It also antagonizes alpha and beta-adrenoceptors. Its primary clinical use is to maintain sinus rhythm and reduce hospitalization risk in patients with paroxysmal or persistent AF/AFL who have returned to normal heart rhythm. Dronedarone should not be used in patients with permanent AF or severe heart failure due to increased risk of mortality and cardiovascular events[2][4][5][9][10].
- Brand names
- Multaq达新宁
- Other names
- dronedarone hydrochloride盐酸决奈达隆决奈达隆盐酸盐
02
Targets
GIRK (G protein-coupled inward-rectifier potassium channel)KCNJ2 (Inward rectifier potassium channel Kir2.1)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)IKs (Slowly activating delayed rectifier potassium channel (KCNQ1/KCNE1))KCNH2 (Voltage-gated potassium channel subfamily H member 2)KCNQ1 (Potassium voltage-gated channel subfamily KQT member 1)SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on dronedarone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dronedarone.